The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Subscribe To Our Newsletter & Stay Updated
